Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00173875
Status:
COMPLETED
Last Update Posted:
2007-07-30
First Post:
2005-09-08
Brief Title:
Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
A Phase II Study to Evaluate the Efficacy and Safety of Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2005-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the overall response rate to Iressa as a first-line treatment in chemonaive patients with inoperable Non-Small Cell Lung Cancer NSCLC
Detailed Description:
The epidermal growth factor receptor EGFR is a promising target for anticancer therapy because it is expressed or highly expressed in a variety of tumors including NSCLCFurthermore high levels of EGFR expression have been associated with a poor prognosis in lung cancer patients in several studies EGFR-targeted cancer therapies are currently being developed strategies include inhibition of the intracellular tyrosine kinase domain of the receptor by small molecules such as gefitinib Iressa ZD1839 AstraZeneca Wilmington DE Iressa is an orally active selective EGFR tyrosine kinase inhibitor that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None